IMMP:NASDAQImmutep Limited Analysis

Immutep (IMMP) is trading at $0.3169, barely above its calculated support of $0.3159 and well below its 20‑day SMA of 0.38, indicating a fragile price floor. The RSI of 11.6 signals extreme oversold conditions, yet the 14‑day MACD histogram is positive and the signal line is labeled bullish, suggesting a possible short‑term bounce that is constrained by a broader bearish trend and a 30‑day volatility of over 500%. Fundamental metrics are distressing: the company reports negative operating margins, a trailing EPS of –$0.41, and a cash‑burn of >$60 M, while its price‑to‑book ratio sits at 6.8×, far above the sector norm, implying the stock is currently overvalued. Recent material news highlights two critical headwinds – a halted Phase III TACTI‑004 trial after a futility analysis and an emerging securities‑fraud lawsuit that could expose the firm to significant legal liabilities. Together, the technical weakness, deteriorating fundamentals, high volatility, and litigation risk create a precarious short‑term outlook, though the pipeline’s long‑term upside remains a speculative catalyst.